CAJ | 학술논문

目的：探讨双次自体造血干细胞移植对恶性血液病的临床疗效。方法：回顾性分析我院 1995年～ 1999年间 12例双次自体造血干细胞移植的资料，并与同期 17例单次自体移植效果比较。结果：双次移植 12例患者移植后持续缓解 6～ 68个月，中位数 27个月，其中 8例（ 66.7％）至今无病生存， 1例于第二次移植后 6个月出现复发， 3例死于移植相关性疾病。单次自体移植 17例患者移植后持续缓解 1～ 36个月，中位数 12个月，其中 6例（ 35.3％）至今无病生存， 8例肿瘤复发， 3例死于移植相关性疾病。结论：双次自体造血干细胞移植治疗恶性血液病的疗效较好，其移植后 18个月生存率有优于单次自体造血干细胞移植的趋势。
목적：탐토쌍차자체조혈간세포이식대악성혈액병적림상료효。방법：회고성분석아원 1995년～ 1999년간 12례쌍차자체조혈간세포이식적자료，병여동기 17례단차자체이식효과비교。결과：쌍차이식 12례환자이식후지속완해 6～ 68개월，중위수 27개월，기중 8례（ 66.7％）지금무병생존， 1례우제이차이식후 6개월출현복발， 3례사우이식상관성질병。단차자체이식 17례환자이식후지속완해 1～ 36개월，중위수 12개월，기중 6례（ 35.3％）지금무병생존， 8례종류복발， 3례사우이식상관성질병。결론：쌍차자체조혈간세포이식치료악성혈액병적료효교호，기이식후 18개월생존솔유우우단차자체조혈간세포이식적추세。
Objective：This study was designed to investigate the outcome of double autologous hematopoietic stem cell transplantation(Double AHSCT) in hematological malignancies. Methods: The clinical data of 12 patients who underwent Double AHSCT between January 1995 and January 1999 were analyzed retrospectively and the outcome were compared with that of 17 patients who received single autologous hematopoietic stem cell transplantation (Single AHSCT) in the same period. Results: The duration of continuous remission in 12 patients undergoing Double AHSCT ranged from 6 to 68 months(mean 27 months). Among them, eight patients (66.7％ ) were still alive without relapse up to now. While one patient had relapsed 6 months after second grafting. Three patients died from diseases related to graft. The patients who received Single AHSCT had a continuous remission of 1－ 36 months after graft (mean 12 months). Six of the 17 patients were still alive in good condition. Eight patients relapsed and 3 patients died from diseases related to graft. Conclusion: Good outcome were showed in Double AHSCT for the treatment of hematological malignancies. The 18 month survival rate in Double AHSCT tended to be better than that in Single AHSCT.